KR20220083760A - Clec12a 항체 단편 서열 및 방법 - Google Patents

Clec12a 항체 단편 서열 및 방법 Download PDF

Info

Publication number
KR20220083760A
KR20220083760A KR1020227016032A KR20227016032A KR20220083760A KR 20220083760 A KR20220083760 A KR 20220083760A KR 1020227016032 A KR1020227016032 A KR 1020227016032A KR 20227016032 A KR20227016032 A KR 20227016032A KR 20220083760 A KR20220083760 A KR 20220083760A
Authority
KR
South Korea
Prior art keywords
ser
gly
amino acid
seq
leu
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020227016032A
Other languages
English (en)
Korean (ko)
Inventor
마틴 펠리시스
제프리 에스. 밀러
Original Assignee
리젠츠 오브 더 유니버시티 오브 미네소타
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 리젠츠 오브 더 유니버시티 오브 미네소타 filed Critical 리젠츠 오브 더 유니버시티 오브 미네소타
Publication of KR20220083760A publication Critical patent/KR20220083760A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
KR1020227016032A 2019-10-17 2020-10-14 Clec12a 항체 단편 서열 및 방법 Pending KR20220083760A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962916340P 2019-10-17 2019-10-17
US62/916,340 2019-10-17
PCT/US2020/055468 WO2021076545A1 (en) 2019-10-17 2020-10-14 Clec12a antibody fragment sequences and methods

Publications (1)

Publication Number Publication Date
KR20220083760A true KR20220083760A (ko) 2022-06-20

Family

ID=75538859

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020227016032A Pending KR20220083760A (ko) 2019-10-17 2020-10-14 Clec12a 항체 단편 서열 및 방법

Country Status (10)

Country Link
US (1) US20240117053A1 (enExample)
EP (1) EP4045540A4 (enExample)
JP (1) JP7796414B2 (enExample)
KR (1) KR20220083760A (enExample)
CN (1) CN114929745B (enExample)
AU (1) AU2020368354B2 (enExample)
BR (1) BR112022007219A2 (enExample)
CA (1) CA3158111A1 (enExample)
IL (1) IL292238A (enExample)
WO (1) WO2021076545A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2021268340A1 (en) * 2020-05-06 2022-12-08 Dragonfly Therapeutics, Inc. Proteins binding NKG2D, CD16 and CLEC12A
CN115850476B (zh) * 2022-08-09 2023-09-05 合源康华医药科技(北京)有限公司 一种cll1抗体及其应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8536310B2 (en) * 2007-10-17 2013-09-17 Arca Biopharma, Inc. Antibodies to CLL-1
EP2245153A4 (en) * 2008-02-13 2011-06-22 Dyax Corp IMPROVED METHODS FOR PRODUCING SPECIFIC BINDING SAVINGS
JP2013508308A (ja) * 2009-10-23 2013-03-07 ガーバン インスティテュート オブ メディカル リサーチ 修飾可変ドメイン分子、ならびにその産生および使用方法
BR112015006824A2 (pt) * 2012-09-27 2017-07-04 Merus B V anticorpo igg biespecífico, método para produzir um anticorpo igg biespecífico, anticorpo, composição farmacêutica e uso de um anticorpo igg biespecífico
CN103467599B (zh) * 2013-09-27 2015-06-17 中国农业科学院兰州兽医研究所 双峰驼源抗猪瘟兔化弱毒疫苗株e2抗原重链抗体vhh和用途
EP3529268B1 (en) * 2016-10-19 2025-02-26 The Scripps Research Institute Chimeric antigen receptor effector cell switches with humanized targeting moieties and/or optimized chimeric antigen receptor interacting domains and uses thereof
MX2019012953A (es) * 2017-05-02 2020-02-12 Alligator Bioscience Ab Anticuerpo biespecifico contra ox40 y ctla-4.
WO2019108065A1 (en) * 2017-12-01 2019-06-06 Merus N.V. Use of bispecific antibody and il-15 for combination therapy
WO2019118918A1 (en) * 2017-12-15 2019-06-20 Aleta Biotherapeutics Inc. Cd19 variants
US11951129B2 (en) * 2018-01-09 2024-04-09 H. Lee Moffitt Cancer Center And Research Institute, Inc. Compositions and methods for targeting CLEC12A-expressing cancers

Also Published As

Publication number Publication date
EP4045540A1 (en) 2022-08-24
JP7796414B2 (ja) 2026-01-09
CA3158111A1 (en) 2021-04-22
CN114929745B (zh) 2025-11-18
AU2020368354A1 (en) 2022-05-12
US20240117053A1 (en) 2024-04-11
WO2021076545A1 (en) 2021-04-22
JP2022553940A (ja) 2022-12-27
EP4045540A4 (en) 2023-11-08
AU2020368354B2 (en) 2026-08-13
IL292238A (en) 2022-06-01
BR112022007219A2 (pt) 2022-07-05
CN114929745A (zh) 2022-08-19

Similar Documents

Publication Publication Date Title
JP7411316B2 (ja) 三重特異性結合タンパク質と使用方法
JP7011574B2 (ja) Ｆｌｔ３及びｃｄ３に対する抗体構築物
JP6738314B2 (ja) Ｂｃｍａおよびｃｄ３に対する結合分子
JP6543197B2 (ja) Ｂｃｍａおよびｃｄ３に対する結合分子
JP2020096630A5 (enExample)
JP2022078246A (ja) 組換え免疫細胞、作製方法、および使用方法
KR102897353B1 (ko) Nk 관여 분자 및 이의 사용 방법
KR102309543B1 (ko) 메소텔린에 특이적으로 결합하는 항-메소텔린 키메릭 항원 수용체
CN115968378A (zh) 靶向b7h3的蛋白质及其使用方法
TWI922434B (zh) 一種融合蛋白及其用途
CN110475857B (zh) 表达抗-可替宁嵌合抗原受体的天然杀伤细胞
JP2022500077A (ja) 改善された抗ｆｌｔ３抗原結合タンパク質
JP2022512672A (ja) アントラサイクリンを含む結合タンパク質－毒素融合体、および免疫腫瘍学的適用におけるその使用
JP7796414B2 (ja) Ｃｌｅｃ１２ａ抗体断片配列及び方法
KR20220087441A (ko) 면역요법 화합물 및 방법
KR102507337B1 (ko) 항 메소텔린 scFv를 포함하는 키메릭 항원 수용체 및 이의 용도
US20240317831A1 (en) Nk cell engager molecules and methods of use
EP3385281A1 (en) Antibody to be cross-linked to human and mouse sema3a, and use thereof
KR20230101444A (ko) 개과 동물의 her1 및 cd3에 특이적으로 결합하는 이중특이적 항체 및 이의 용도
HK40064939A (en) Trispecific binding proteins and methods of use
CN120192422A (zh) 双特异性抗体及其应用

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

D21 Rejection of application intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000